干扰素2α联合力尔凡治疗转移性肾癌  

United Treatment of Lifein and Interferon-2α in Metastatic Renal Carcinoma

作　　者：许尔屹[1] 王莉彦[1] 王玥玲[1] 

机构地区：[1]黑龙江省医院,黑龙江哈尔滨150001

出　　处：《黑龙江医学》2011年第5期352-353,共2页Heilongjiang Medical Journal

摘　　要：目的探讨干扰素2α联合力尔凡治疗转移性肾癌的疗效。方法对18例转移性肾癌患者应用干扰素2α300万U/次,每周3次。第5周开始联合力尔凡治疗,5.0 mg/d,皮下注射,连用5 d,然后给予10 mg/d,静滴,连用25 d,2个月为1疗程,至少2个疗程。结果随访5～38个月,完全缓解1例,部分缓解7例,病灶无变化3例,病灶进展7例。缓解病例均为透明细胞癌。结论干扰素联合力尔凡治疗转移性肾癌,能缓解症状,延长生存期。Objective To investigate the effect of interferon-2α combined with Lifein in the treatment of metastatic renal carcinoma.Methods 18 cases of such patients were treated with interferon-2α,300 million U per times,3 times a week.Lifein united treatment after 5 weeks,5.0 mg/d subcutaneously,for 5 d,then 10 mg/d intravenously,once every 25 d,2 months,1 course of treatment,at least 2 courses.Results The cases were followed-up 5 to 38 months.1 case was complete remission,partial remission in 7 cases,the lesions did not change in 3 cases,7 cases of disease progression.All catabatic cases were clear cell carcinoma.Conclusion United treatment of interferon-2α and Lifein,can relieve symptoms and prolong survival in metastatic renal carcinoma.

关 键 词：干扰素 力尔凡 肾肿瘤 预后 

分 类 号：R967[医药卫生—药理学]